A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction
Authors:
- Angel ArnaoutAAAngel Arnaout
- Jing ZhangJZJing Zhang
- Simon FrankSFSimon Frank
- Moein MomtaziMMMoein Momtazi
- Erin CordeiroECErin Cordeiro
- Amanda RobertsARAmanda Roberts
- Ammara GhummanAGAmmara Ghumman
- Dean FergussonDFDean Fergusson
- Carol StoberCSCarol Stober
- Gregory PondGPGregory Pond
- Ahwon JeongAJAhwon Jeong
- Lisa VandermeerLVLisa Vandermeer
Open Access
- 25 December 2020
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 28 (1) , 184-195
Abstract
Background: The effectiveness of different acellular dermal matrices (ADM) used for implant-based reconstruction immediately following mastectomy is an important clinical question. A prospective randomized clinical trial was performed to evaluate the superiority of DermACELL over Alloderm-RTU in reducing drain duration. Methods: Patients undergoing mastectomy with subpectoral immediate and permanent implant-based breast reconstruction were randomized to Alloderm-RTU or DermACELL. The primary outcome was seroma formation, measured by the duration of postoperative drain placement. Secondary outcomes included: post drain removal seroma aspiration, infection, redbreast syndrome, wound dehiscence, loss of the implant, and unplanned return to the operating room. Results: 62 patients were randomized for 81 mastectomies (41 Alloderm-RTU, 40 DermACELL). Baseline characteristics were similar. There was no statistically significant difference in mean drain duration (p = 0.16), with a trend towards longer duration in the Alloderm-RTU group (1.6 days; 95%CI, 0.7 to 3.9). The overall rate of minor and major complications were statistically similar between the two groups; although patients with Alloderm-RTU had 3 times as many infections requiring antibiotics (7.9% vs. 2.5%) with a risk difference of 5.4 (95%CI −4.5 to 15.2), and twice as many unplanned returns to the operating room (15.8% vs. 7.5%) with a risk difference of 8.3 (95% CI −5.9 to 22.5) as DermACELL. Conclusion: This is the first prospective randomized clinical trial comparing the two most commonly used human-derived ADMs. There was no statistically significant difference in drain duration, minor, or major complications between DermACELL over Alloderm-RTU in immediate subpectoral permanent implant-based breast reconstruction post-mastectomy.Keywords
This publication has 43 references indexed in Scilit:
- Biologic matrices in oncologic breast reconstruction after mastectomyExpert Review of Medical Devices, 2013
- Economic Analysis and Review of the Literature on Implant-Based Breast Reconstruction With and Without the Use of the Acellular Dermal MatrixAesthetic Plastic Surgery, 2013
- Acellular dermal matrix (ADM) assisted breast reconstruction proceduresEuropean Journal of Surgical Oncology, 2013
- A Paradigm Shift in U.S. Breast ReconstructionPlastic and Reconstructive Surgery, 2013
- Evaluation of Host Tissue Integration, Revascularization, and Cellular Infiltration Within Various Dermal SubstratesAnnals of Plastic Surgery, 2012
- Comparison of Different ADM Materials in Breast SurgeryClinics in Plastic Surgery, 2012
- A Systematic Review and Meta-Analysis of Complications Associated With Acellular Dermal Matrix-Assisted Breast ReconstructionAnnals of Plastic Surgery, 2012
- Retrospective Review of 331 Consecutive Immediate Single-Stage Implant Reconstructions with Acellular Dermal MatrixPlastic and Reconstructive Surgery, 2011
- The Use of AlloDerm in Postmastectomy Alloplastic Breast Reconstruction: Part II. A Cost AnalysisPlastic and Reconstructive Surgery, 2011
- An 8-Year Experience of Direct-to-Implant Immediate Breast Reconstruction Using Human Acellular Dermal Matrix (AlloDerm)Plastic and Reconstructive Surgery, 2011